US 9593162
Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
granted A61KA61K2039/505A61K51/1072
Quick answer
US patent 9593162 (Internalizing human monoclonal antibodies targeting prostate cancer cells in situ) held by The Regents of the University of California expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Regents of the University of California
- Grant date
- Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K2039/505, A61K51/1072, A61P, A61P35/00